CD30 is specifically and abundantly expressed by immune cells especially Reed-Sternberg cells (Anaplastic large-cells), typical for Hodgkin’s lymphoma, and in embryonal carcinoma, which makes CD30 an ideal target for anticancer monoclonal antibody therapy (Figure 4). This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.